Differences in humoral immunogenicity between herpes simplex virus types 1 and 2

Area of Science:

• Virology
• Immunology

Background:

• Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are common human pathogens.
• Understanding differential immune responses to HSV strains is crucial for vaccine development and disease management.

Purpose of the Study:

• To compare the antibody-stimulating potency of different HSV-1 and HSV-2 strains in a mouse model.
• To investigate the impact of immune-modulating drugs on antibody responses.
• To assess secondary immune responses following primary HSV infections.

Main Methods:

• Infection of NMRI mice with various doses of HSV-1 and HSV-2 strains.
• Measurement of neutralizing antibody levels.
• Quantification of viral content in organs.
• Administration of immune-modulating drugs (silica, poly(I) X poly(C)-lys-CM-cellulose).
• Evaluation of secondary immune responses after primary infections.

Main Results:

• Increasing doses of HSV-1 induced dose-dependent neutralizing antibody responses.
• Most HSV-2 strains elicited only marginal antibody responses, with one exception (HG 52) at high doses.
• HSV-2 infections generally resulted in lower viral organ content compared to HSV-1.
• Immune-modulating drugs showed limited augmentation of antibody formation.
• Primary HSV-1 infection led to robust secondary responses, while primary HSV-2 infection suppressed secondary responses to both HSV-1 and HSV-2.

Conclusions:

• Significant differences exist in the immunogenicity of HSV-1 and HSV-2 strains.
• HSV-1 is a more potent stimulator of neutralizing antibody production than most HSV-2 strains.
• HSV-2 infections may have immunosuppressive effects on subsequent viral challenges, highlighting distinct immune evasion strategies.